The GLOW trial was a multicenter, randomized phase III trial to evaluate the efficacy of zolbetuximab on CAPOX in HER2-negative and CLDN18.2-positive patients with metastatic or advanced G/GEJ adenocarcinomas [9]. The gene discussed is ERBB2; the disease is gastroesophageal junction adenocarcinoma.